Wu Jingdong, Yang Yongfei, Song Jiansheng
Department of Emergency Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hebei 430010, P.R. China.
Oncol Lett. 2020 Nov;20(5):182. doi: 10.3892/ol.2020.12043. Epub 2020 Aug 31.
The present study aimed to investigate the expression and clinical significance of solute carrier family 17 member 9 (SLC17A9) in cancer tissues of patients with hepatocellular carcinoma (HCC). Ninety-eight patients with HCC were admitted to our hospital from January 2010 to December 2014. Their clinical data was retrospectively analyzed. The expression of SLC17A9 in HCC cancer tissues was detected by immunohistochemistry. Kaplan-Meier curve, log-rank test and Cox proportional hazard model analysis were used to analyze the tumor-free survival rate and overall survival rate. SLC17A9 expression was associated with Edmondson grade (P=0.04) and distant metastasis (P=0.03). The tumor-free survival (P=0.03) and overall survival (P=0.01) of SLC17A9-high expression patients were significantly lower than those in SLC17A9-low expression patients. Multivariate analysis revealed that SLC17A9 expression (HR, 0.77; 95% CI, 0.27-2.47, P=0.02) was an independent risk factor for tumor-free survival in patients with HCC, and the expression of SLC17A9 (HR, 1.81; 95% CI, 0.99-3.77, P=0.04) was an independent risk factor for overall survival in patients with HCC. In conclusion, SLC17A9 can be used as a new molecular marker to predict the poor prognosis of patients with HCC.
本研究旨在探讨溶质载体家族17成员9（SLC17A9）在肝细胞癌（HCC）患者癌组织中的表达及其临床意义。2010年1月至2014年12月，我院收治了98例HCC患者。对其临床资料进行回顾性分析。采用免疫组织化学法检测HCC癌组织中SLC17A9的表达。运用Kaplan-Meier曲线、对数秩检验和Cox比例风险模型分析无瘤生存率和总生存率。SLC17A9表达与Edmondson分级（P=0.04）和远处转移（P=0.03）相关。SLC17A9高表达患者的无瘤生存率（P=0.03）和总生存率（P=0.01）显著低于SLC17A9低表达患者。多因素分析显示，SLC17A9表达（HR，0.77；95%CI，0.27-2.47，P=0.02）是HCC患者无瘤生存的独立危险因素，SLC17A9表达（HR，1.81；95%CI，0.99-3.77，P=0.04）是HCC患者总生存的独立危险因素。综上所述，SLC17A9可作为预测HCC患者预后不良的新分子标志物。
